Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
>
Disorders
>
Disease or Syndrome
>
Chronic Infection
Chronic Infection
Chronic Infection is a persistent, long-lasting infection that can have significant impacts on an individual's health and well-being.
These infections may be caused by a variety of pathogens, including bacteria, viruses, fungi, or parasites, and can affect various body systems.
Chronic infections are oftne characterized by recurrent or continuous symptoms, and may require prolonged treatment to manage or eradicate the underlying infection.
Understanding the epidemiology, pathogenesis, and optimal treatment approaches for chronic infections is crucial for improving patient outcomes and reducing the burden of these persistent health conditions.
Advancements in diagnostic techniques and therapeutic interventions continue to evolve the management of chronic infections.
These infections may be caused by a variety of pathogens, including bacteria, viruses, fungi, or parasites, and can affect various body systems.
Chronic infections are oftne characterized by recurrent or continuous symptoms, and may require prolonged treatment to manage or eradicate the underlying infection.
Understanding the epidemiology, pathogenesis, and optimal treatment approaches for chronic infections is crucial for improving patient outcomes and reducing the burden of these persistent health conditions.
Advancements in diagnostic techniques and therapeutic interventions continue to evolve the management of chronic infections.
Most cited protocols related to «Chronic Infection»
Adult
Antiviral Agents
Bone Marrow Transplantation
Chronic Infection
Coinfection
Disease Progression
Hepatitis A
Hepatitis B Surface Antigens
HIV
Patients
Therapeutics
Vision
Woman
The Prospective Evaluation of Antiretrovirals in Resource Limited Settings
(PEARLS) study of the AIDS Clinical Trials Group (ACTG) evaluated two
hypotheses: (1) Antiretroviral regimens administered once daily are non-inferior
to twice-daily regimens; (2) A regimen containing ATV administered once daily
without ritonavir boosting is non-inferior to an EFV-based regimen. Study design
details are available at ClinicalTrials.gov NCT00084136 and in the study
protocol provided inText S1 . The CONSORT checklist used for
preparation of this manuscript is provided inText
S2 .
Enrollment was limited to the following ACTG international sites: Instituto de
Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil; Hospital Nossa Senhora
da Conceicao-GHC, Porto Alegre, Brazil; Les Centres GHESKIO, Port-au-Prince,
Haiti; YRG Centre for AIDS Research & Education, Chennai, India; National
AIDS Research Institute, Pune, India; College of Medicine Clinical Research
Site, Blantyre, Malawi; Kamuzu Central Hospital, Lilongwe, Malawi; Asociacion
Civil Impacta Salud y Educacion - Miraflores and San Miguel Clinical Research
Site, Lima, Peru; Durban Adult HIV Clinical Research Site, Durban, South Africa;
University of Witwatersrand Clinical HIV Research Unit, Johannesburg, South
Africa; Research Institute for Health Sciences, Chiang Mai, Thailand; and
Parirenyatwa Hospital Clinical Research Center, Harare, Zimbabwe. All ACTG sites
in the United States were also eligible to enroll participants. Enrollment in
the US was limited to no more than 18% of total; the remaining enrollment was
distributed equally across the international sites with an option for
international sites to request additional enrollment once their initial quota of
100 participants was filled.
Eligible participants were ≥18 y, had documented HIV-1 infection, CD4+
lymphocytes <300 cells/µl, and ≤7 d of cumulative antiretroviral therapy
prior to study entry. Persons with absolute neutrophils <750/µl, hemoglobin
<7.5 g/dl, calculated creatinine clearance <60 ml/min, or aspartate
transaminase or alanine transaminase greater than 5-fold above the upper limit
of normal were excluded. Women of reproductive potential were non-pregnant and,
if participating in sexual activity that could lead to pregnancy, agreed to use
contraception (two forms if taking EFV). Persons with serious chronic, acute, or
recurrent infections had completed ≥14 d of therapy and were clinically
stable.
(PEARLS) study of the AIDS Clinical Trials Group (ACTG) evaluated two
hypotheses: (1) Antiretroviral regimens administered once daily are non-inferior
to twice-daily regimens; (2) A regimen containing ATV administered once daily
without ritonavir boosting is non-inferior to an EFV-based regimen. Study design
details are available at ClinicalTrials.gov NCT00084136 and in the study
protocol provided in
preparation of this manuscript is provided in
S2
Enrollment was limited to the following ACTG international sites: Instituto de
Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil; Hospital Nossa Senhora
da Conceicao-GHC, Porto Alegre, Brazil; Les Centres GHESKIO, Port-au-Prince,
Haiti; YRG Centre for AIDS Research & Education, Chennai, India; National
AIDS Research Institute, Pune, India; College of Medicine Clinical Research
Site, Blantyre, Malawi; Kamuzu Central Hospital, Lilongwe, Malawi; Asociacion
Civil Impacta Salud y Educacion - Miraflores and San Miguel Clinical Research
Site, Lima, Peru; Durban Adult HIV Clinical Research Site, Durban, South Africa;
University of Witwatersrand Clinical HIV Research Unit, Johannesburg, South
Africa; Research Institute for Health Sciences, Chiang Mai, Thailand; and
Parirenyatwa Hospital Clinical Research Center, Harare, Zimbabwe. All ACTG sites
in the United States were also eligible to enroll participants. Enrollment in
the US was limited to no more than 18% of total; the remaining enrollment was
distributed equally across the international sites with an option for
international sites to request additional enrollment once their initial quota of
100 participants was filled.
Eligible participants were ≥18 y, had documented HIV-1 infection, CD4+
lymphocytes <300 cells/µl, and ≤7 d of cumulative antiretroviral therapy
prior to study entry. Persons with absolute neutrophils <750/µl, hemoglobin
<7.5 g/dl, calculated creatinine clearance <60 ml/min, or aspartate
transaminase or alanine transaminase greater than 5-fold above the upper limit
of normal were excluded. Women of reproductive potential were non-pregnant and,
if participating in sexual activity that could lead to pregnancy, agreed to use
contraception (two forms if taking EFV). Persons with serious chronic, acute, or
recurrent infections had completed ≥14 d of therapy and were clinically
stable.
Full text: Click here
Acquired Immunodeficiency Syndrome
Adult
Alanine Transaminase
CD4 Positive T Lymphocytes
Cells
Chronic Infection
Creatinine
Hemoglobin
HIV Infections
Neutrophil
Pregnancy
Reproduction
Ritonavir
Therapeutics
Treatment Protocols
Woman
We used a simple target cell limited model to describe SARS-CoV-2, SARS-CoV, and MERS-CoV viral dynamics [20 (link),24 (link),67 (link)]. Target cell limited models have proved very valuable in understanding infection dynamics and therapy for chronic viral infections such as HIV [61 (link),68 (link)], HCV [69 (link)], and HBV [70 (link)] and for acute infections such as influenza [71 (link)], West Nile virus [72 (link)], Zika virus [73 (link)], and SARS-CoV-2 [17 (link),74 (link),75 (link)]. Although the model does not explicitly describe immune responses, the effects of immune responses are implicitly included in model parameters such as the infection rate, which can be influenced by innate responses, and the death rate of infected cells, which can be influenced by adaptive immune responses. Because of the simplicity of the model, these parameters can be estimated and compared among the 3 different coronaviruses. The form of the model that we use was first introduced to model influenza infection [71 (link)] and is given by
where the variables T(t), I(t), and V(t) are the number of uninfected target cells, the number of infected target cells, and the amount of virus at time t (note: we used time after symptom onset as the timescale), respectively. Symptom onset is defined slightly differently between papers, but it essentially means when any coronavirus-related symptoms (fever, cough, and shortness of breath) appear [76 ]. The parameters β, δ, p, and c represent the rate constant for virus infection, the death rate of infected cells, the per cell viral production rate, and the per capita clearance rate of the virus, respectively. Since the clearance rate of the virus is typically much larger than the death rate of the infected cells in vivo [27 (link),67 (link),77 ], we made a quasi-steady state (QSS) assumption, dV(t)/dt = 0, and replacedEq 3 with V(t) = pI(t)/c. Because data on the numbers of coronavirus RNA copies, V(t), rather than the number of infected cells, I(t), were available, I(t) = cV(t)/p was substituted into Eq 2 to obtain
Furthermore, we replaced T(t) by the fraction of target cells remaining at time t, i.e., f(t) = T(t)/T(0), where T(0) is the initial number of uninfected target cells. Note f(0) = 1. Accordingly, we obtained the following simplified mathematical model, which we employed to analyze the viral load data in this study:
where γ = pβT(0)/c corresponds to the maximum viral replication rate under the assumption that target cells are continuously depleted during the course of infection. Thus, f(t) is equal to or less than 1 and continuously declines.
In our analyses, the variable V(t) corresponds to the viral load for SARS-CoV-2, MERS-CoV, and SARS-CoV (copies/ml). Because all of them cause acute infection, loss of target cells by physiological turnover can be ignored, considering the long lifespan of the target cells.
where the variables T(t), I(t), and V(t) are the number of uninfected target cells, the number of infected target cells, and the amount of virus at time t (note: we used time after symptom onset as the timescale), respectively. Symptom onset is defined slightly differently between papers, but it essentially means when any coronavirus-related symptoms (fever, cough, and shortness of breath) appear [76 ]. The parameters β, δ, p, and c represent the rate constant for virus infection, the death rate of infected cells, the per cell viral production rate, and the per capita clearance rate of the virus, respectively. Since the clearance rate of the virus is typically much larger than the death rate of the infected cells in vivo [27 (link),67 (link),77 ], we made a quasi-steady state (QSS) assumption, dV(t)/dt = 0, and replaced
Furthermore, we replaced T(t) by the fraction of target cells remaining at time t, i.e., f(t) = T(t)/T(0), where T(0) is the initial number of uninfected target cells. Note f(0) = 1. Accordingly, we obtained the following simplified mathematical model, which we employed to analyze the viral load data in this study:
where γ = pβT(0)/c corresponds to the maximum viral replication rate under the assumption that target cells are continuously depleted during the course of infection. Thus, f(t) is equal to or less than 1 and continuously declines.
In our analyses, the variable V(t) corresponds to the viral load for SARS-CoV-2, MERS-CoV, and SARS-CoV (copies/ml). Because all of them cause acute infection, loss of target cells by physiological turnover can be ignored, considering the long lifespan of the target cells.
Full text: Click here
Cell Death
Chronic Infection
Coronavirus Infections
Cough
Dyspnea
Fever
Head
Infection
Influenza
Metabolic Clearance Rate
Middle East Respiratory Syndrome Coronavirus
physiology
Response, Humoral Immune
Response, Immune
SARS-CoV-2
Severe acute respiratory syndrome-related coronavirus
Therapeutics
Virus
Virus Diseases
Virus Replication
West Nile virus
Zika Virus
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
Antihypertensive Agents
Arthritis
Blood Pressure
Cerebrovascular Accident
Chronic Infection
Diabetes Mellitus
Digestive System Disorders
Disease, Chronic
Dyslipidemias
Food
Head
Health Services, Outpatient
Heart Diseases
High Blood Pressures
Hospitalization
Households
Inpatient
Kidney Diseases
Liver Diseases
Lung
Lung Diseases
Malignant Neoplasms
Memory Disorders
Mental Recall
Noncommunicable Diseases
Nurses
Outpatients
Physical Examination
Pressure, Diastolic
Systole
Systolic Pressure
We estimated the number of chronic HBV infections prevented in the 1992–2013 birth cohorts by using Goldstein’s model, which was used in the 2006 survey to estimate baseline disease prevalence and cases prevented (21 (link)). This model provides estimates of total numbers of cases and deaths caused by acute HBV infection and numbers of cases and sequelae from chronic HBV infection, including cirrhosis and primary hepatocellular carcinoma that would develop during the lifetime of a birth cohort. The key inputs to the model are baseline HBsAg seroprevalence in the entire population and among women of childbearing age and HepB coverage. Figures on the effect of vaccination by birth cohort were summed to estimate the overall effect by using birth cohort sizes of 16.97 million persons per year. We assumed a baseline HBsAg prevalence of 8.58% among women of childbearing age, uniformly distributed, with 30% also being HBeAg positive. Among 5-year-old children, 32% were assumed to become chronically HBV-infected (anti-HBc positive) by 5 years of age and 55% to be chronically infected by 30 years of age; these percentages represented force of infection without vaccination (6 (link),20 ).
Full text: Click here
Birth Cohort
Child
Chronic Infection
Cirrhosis
gamma-hydroxy-gamma-ethyl-gamma-phenylbutyramide
Hepatitis B Surface Antigens
Hepatocellular Carcinomas
Infection
sequels
Vaccination
Woman
Most recents protocols related to «Chronic Infection»
Example 20
Fertility—Progesterone is one of the most important hormones for pregnancy with myriad functions from ensuring implantation of the egg into a healthy uterine wall, to ensuring embryo survival and prevention of immune rejection of the developing baby. Many other hormones act in concert with progesterone, like Follicular Stimulating Hormone (FSH) and Luteinizing Hormone (LH) and can be used to assess optimal fertility windows on a monthly basis. And in fact an over dominant production of estrogen can lead to progesterone deficiency and thus difficulty getting or staying pregnant. It is important that women not only monitor FSH and LH to determine optimal fertility for getting pregnant, but ensure that sufficient levels or progesterone are being produced to ensure pregnancy and viability of the fetus. A study from the British Medical Journal, 2012, demonstrated that a single progesterone level test can help discriminate between viable and nonviable pregnancies. Among women who had an ultrasound, 73 percent had nonviable pregnancies. But among women with progesterone levels below 3 to 6 nanograms per milliliter, the probability of a nonviable pregnancy rose to more than 99 percent (Gallos L et al. British Medical J, 2012).
Perimenopause—Monitoring hormone levels during the menopausal transition may help women better understand important changes in their body and allow them to make more informed decisions about health, diet, and lifestyle. According to Hale G E (Best Pract Res Clin Obstet Gynaecol, 2009), data from endocrine studies on women throughout the menopausal transition show changes in levels of steroid hormones and gonadotropins (Progesterone, Estrodiol, LH, FSH and AMH) and follicle-stimulating hormone undergoes the first detectable change while menstrual cycles remain regular. Erratic and less predictable changes in steroid hormones follow, especially with the onset of irregular cycles. Later serum hormone studies on the inhibins and anti-Mullerian hormone established that diminishing ovarian follicle number contributes to the endocrine changes with advancing reproductive age.
Many fertility issues revolve around genetic, anatomical or other disorders that may either prevent a woman from becoming pregnant and/or staying pregnant. Some of these disorders include hormonal imbalances, diabetes, a short or insufficient cervix, and acute or chronic infections. A cascade of genes has been implicated in the occurrence of getting and staying pregnant. These genes have been studied using genotyping, gene expression, and proteomic analysis to assess a woman's ability to stay pregnant.
In some embodiments the disclosed device focuses on detecting levels of Progesterone, LH, FSH, Estrodiol, AMH, genotyping, gene expression through RNA and methylome sequencing, qPCR and proteomic analysis for fertility and menopause management from menstrual blood or cervicovaginal fluid.
Full text: Click here
BLOOD
Cervix Uteri
Chronic Infection
Diabetes Mellitus
Diet
Embryo
Endocrine System Diseases
Epigenome
Estrogens
Fertility
Fetal Viability
Follicle-stimulating hormone
Gene Expression
Genes
Genes, vif
Gonadotropins
Hormones
Human Body
Human Follicle Stimulating Hormone
Infant
Inhibin
Luteinizing hormone
Medical Devices
Menopause
Menstrual Cycle
Menstruation
Mullerian-Inhibiting Hormone
Ovarian Follicle
Ovum Implantation
Perimenopause
Pregnancy
Progesterone
Reproduction
Steroids
System, Endocrine
Transcription, Genetic
Ultrasonography
Uterus
Woman
Example 51
The NOD SCID gamma mouse model of chronic, asymptomatic C. parvum infection was used to test in vivo compound efficacy. NOD SCID gamma mice were infected with ˜1×105 C. parvum oocysts by oral gavage 5-7 days after weaning. The infected animals begin shedding oocysts in the feces 1 week after infection, which is measured by quantitative PCR (qPCR). Based on experience with the positive control compound paromomycin, four mice are required per experimental group to achieve 80% power to detect an 80% percent reduction in parasite shedding after four days of drug compound. In additional to the experimental drug regimen groups, additional negative (gavage with DMSO/methylcellulose carrier) and positive (paromomycin 2000 mg/kg once daily) control groups are included in each experiment. Mice are infected 5-7 days after weaning (day −6), infection is confirmed 1 week later (day 0), and experimental compounds are dosed by oral gavage on days 1-4. The dosing frequency was as indicated. Treatment efficacy was assessed by measurement of fecal oocyst shedding by qPCR on day 5.
Full text: Click here
Animals
Asymptomatic Infections
Biological Assay
Chronic Infection
Drug Compounding
Feces
Gamma Rays
Infection
Investigational New Drugs
Methylcellulose
Mice, Inbred NOD
Mus
Oocysts
Parasites
Paromomycin
SCID Mice
Sulfoxide, Dimethyl
Treatment Protocols
Tube Feeding
Two hundred and ten individuals were willing to join this study (May 10, 2021, to July 1, 2022). The exclusion criteria for the two groups were as follows: type 1 diabetes mellitus, impaired fasting glucose or impaired glucose tolerance58 (link), hypertension, hypoglycemia (blood sugar levels < 3.9 mmol/L), hyperlipidemia, serious eye diseases (e.g., blindness), symptoms of neurological conditions (e.g., cerebral infarction or hemorrhage), history of neurological abnormality (e.g., Parkinson’s disease), severe head injuries or chronic head discomfort (e.g., migraine), BMI > 31 kg/m2, left- or mixed-handedness, substance (tobacco, alcohol, or psychoactive drug) abuse, taking medications that may affect cognition and memory within 6 months, specific abnormalities detected on conventional MRI scans or any other factors that may influence brain structure or function (e.g., extreme physical weakness, chronic infections, and other endocrine diseases). Patients with T2DM were diagnosed by two experienced endocrinologists following international clinical standards59 . MCI was evaluated via Mini-Mental State Examination (MMSE) and MoCA-B (21 ≤ MoCA-B score < 26, and MMSE score > 24 were diagnosed with MCI)60 ,61 (link).
Participants with brain tumors (n = 3), neuropsychiatric diseases (n = 4) (e.g., major depression or schizophrenia), or developmental disorders (n = 4) were excluded. Finally, 37 patients with T2DM-MCI, 93 patients with T2DM-NCI, and 69 NC were enrolled in this study. The source of patients with T2DM and NC corresponded with our previous study37 (link). This study was approved by the ethics committee of The First Affiliated Hospital of Guangzhou University of Chinese Medicine (ID: NO. JY [2020] 288). Written informed consent was obtained from all participants. In addition, the study was conducted following approved guidelines.
Participants with brain tumors (n = 3), neuropsychiatric diseases (n = 4) (e.g., major depression or schizophrenia), or developmental disorders (n = 4) were excluded. Finally, 37 patients with T2DM-MCI, 93 patients with T2DM-NCI, and 69 NC were enrolled in this study. The source of patients with T2DM and NC corresponded with our previous study37 (link). This study was approved by the ethics committee of The First Affiliated Hospital of Guangzhou University of Chinese Medicine (ID: NO. JY [2020] 288). Written informed consent was obtained from all participants. In addition, the study was conducted following approved guidelines.
Full text: Click here
Asthenia
Blindness
Blood Glucose
Brain
Brain Neoplasms
Cerebral Infarction
Chinese
Chronic Infection
Cognition
Congenital Abnormality
Craniocerebral Trauma
Developmental Disabilities
Diabetes Mellitus, Insulin-Dependent
Drug Abuse
Endocrine System Diseases
Endocrinologists
Ethanol
Ethics Committees, Clinical
Eye Disorders
Glucose
Head
Hemorrhage
High Blood Pressures
Hyperlipidemia
Hypoglycemia
Major Depressive Disorder
Memory
Migraine Disorders
Mini Mental State Examination
MRI Scans
Nervous System Abnormality
Nervous System Disorder
Patients
Pharmaceutical Preparations
Physical Examination
Psychotropic Drugs
Schizophrenia
Tobacco Products
This retrospective study reviewed medical charts was performed in a center for maternal, fetal, and neonatal medicine in Haseki Training and Research Hospital, with 89 pregnant women admitted with placental abruption. There were 7077 pregnant women who were delivered between 2016 and 2020 in the study period. The approval of the Haseki Training and Research Hospital Clinical Research Ethics Committee was obtained for this study (date: August 04, 2021, number: 62-2021) and the valid Helsinki Declaration. At the first admission, the diagnosis of placental abruption was confirmed primarily on ultrasonographic examination or one or more of the following clinical features, including uterine tenderness, abdominal pain, and vaginal bleeding or with or without abnormal fetal heart activity. Placental abruption was reconfirmed during cesarean delivery by local examination of the placenta for separation and the presence of a retroplacental hematoma. The suspected placenta was sent to the Pathology Laboratory to confirm the presence of the abruption.
Medical charts of the study participants for this period were screened for baseline clinical, obstetric and ultrasonographic features, presence of stillbirth, pre-and post-delivery laboratory results, required transfusion and its amount, and neonatal outcomes of women with placental abruption with or without stillbirth were collected. A composite poor maternal outcome was recorded if any of the following features were present: hemorrhagic shock and DIC. The results of the hemogram tests, which are the targeted parameters of the study and routinely applied both at admission and 4 h postoperatively, were recorded. Exclusion criteria included clinical conditions, including known acute or chronic maternal infections, hematological disorders (disorders affecting thrombocyte function and hematological cancers), and chronic systemic disorders affecting the results of complete blood count.
Medical charts of the study participants for this period were screened for baseline clinical, obstetric and ultrasonographic features, presence of stillbirth, pre-and post-delivery laboratory results, required transfusion and its amount, and neonatal outcomes of women with placental abruption with or without stillbirth were collected. A composite poor maternal outcome was recorded if any of the following features were present: hemorrhagic shock and DIC. The results of the hemogram tests, which are the targeted parameters of the study and routinely applied both at admission and 4 h postoperatively, were recorded. Exclusion criteria included clinical conditions, including known acute or chronic maternal infections, hematological disorders (disorders affecting thrombocyte function and hematological cancers), and chronic systemic disorders affecting the results of complete blood count.
Abdominal Pain
Abruptio Placentae
Blood Platelets
Blood Transfusion
Care, Prenatal
Cesarean Section
Chronic Infection
Complete Blood Count
Diagnosis
Disease, Chronic
Ethics Committees, Clinical
Ethics Committees, Research
Fetal Heart
Hematological Disease
Hematologic Neoplasms
Hematoma
Infant, Newborn
Mothers
Obstetric Delivery
Pharmaceutical Preparations
Placenta
Pregnant Women
Shock, Hemorrhagic
Training Programs
Uterus
Woman
The study population comprised 14 healthy individuals and 38 SLE subjects divided into the following groups: 27 inactive lupus (SLEDAI ≤6), 11 with active disease (SLEDAI >6) were recruited from the department of Immunology and Rheumatology of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. All SLE patients fulfilled ACR/SLICC 2012 classification criteria (28 (link)), and disease activity was addressed by the SLE disease activity index (SLEDAI). We excluded subjects with ongoing acute or chronic infections (i.e., HIV or viral hepatitis), pregnancy, and patients with a diagnosis of other concomitant autoimmune diseases except for antiphospholipid (aPL) syndrome. None of the study participants received any B cell-depleting or other biological therapies. This study was approved by the Institutional Ethics and Research Committees of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (Ref. 2306). The patients/participants provided their written informed consent to participate prior to inclusion in the study. Demographic and Clinical characteristics of the study population are depicted in Table 1
Full text: Click here
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl
Antiphospholipid Syndrome
Autoimmune Diseases
B-Lymphocytes
Chronic Infection
Diagnosis
Hepatitis Viruses
Lupus Vulgaris
Patients
Pregnancy
Therapies, Biological
Top products related to «Chronic Infection»
Sourced in France, United States
FibroScan is a non-invasive diagnostic device that uses vibration-controlled transient elastography (VCTE) technology to measure liver stiffness. The device transmits a mild vibration through the skin and measures the velocity of the resulting shear wave, which is directly related to the stiffness of the liver tissue. This information can be used to assess the degree of liver fibrosis.
Sourced in United States, Denmark, Austria, United Kingdom, Japan, Canada
Stata version 14 is a software package for data analysis, statistical modeling, and graphics. It provides a comprehensive set of tools for data management, analysis, and reporting. Stata version 14 includes a wide range of statistical techniques, including linear regression, logistic regression, time series analysis, and more. The software is designed to be user-friendly and offers a variety of data visualization options.
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
Sourced in United States, China, Japan, Germany, United Kingdom, Canada, France, Italy, Australia, Spain, Switzerland, Netherlands, Belgium, Lithuania, Denmark, Singapore, New Zealand, India, Brazil, Argentina, Sweden, Norway, Austria, Poland, Finland, Israel, Hong Kong, Cameroon, Sao Tome and Principe, Macao, Taiwan, Province of China, Thailand
TRIzol reagent is a monophasic solution of phenol, guanidine isothiocyanate, and other proprietary components designed for the isolation of total RNA, DNA, and proteins from a variety of biological samples. The reagent maintains the integrity of the RNA while disrupting cells and dissolving cell components.
Sourced in United States, Germany, Switzerland, Japan
The Cobas TaqMan HCV Test v2.0 is an in vitro diagnostic test used for the quantitative detection of Hepatitis C Virus (HCV) RNA in human serum or plasma samples. The test utilizes real-time PCR technology to measure the viral load of HCV.
Sourced in United States, Switzerland, Germany, Japan, United Kingdom, France, Canada, Italy, Macao, China, Australia, Belgium, Israel, Sweden, Spain, Austria
DNase I is a lab equipment product that serves as an enzyme used for cleaving DNA molecules. It functions by catalyzing the hydrolytic cleavage of phosphodiester bonds in the DNA backbone, effectively breaking down DNA strands.
Sourced in United States, Germany, France
The RealTime HCV assay is a laboratory test designed to detect and quantify hepatitis C virus (HCV) RNA in human plasma or serum samples. The assay utilizes real-time PCR technology to provide quantitative results for HCV viral load measurements.
Sourced in Switzerland, China, United States
Pegasys is a laboratory equipment product manufactured by Roche. It serves as a precision tool for scientific research and clinical applications. The core function of Pegasys is to provide a reliable and consistent platform for various laboratory analyses and experiments.
Sourced in United States, United Kingdom, Finland, Singapore, China, Germany, Canada
The Varioskan LUX Multimode Microplate Reader is a versatile laboratory instrument designed for various fluorescence, absorbance, and luminescence-based assays. It is capable of detecting a wide range of signals from 96- or 384-well microplates.
More about "Chronic Infection"
Chronic infections are persistent, long-lasting health conditions caused by a variety of pathogens, including bacteria, viruses, fungi, or parasites.
These infections can affect different body systems and often lead to recurrent or continuous symptoms, requiring prolonged treatment for management or eradication.
Understanding the epidemiology, pathogenesis, and optimal treatment approaches for chronic infections is crucial for improving patient outcomes and reducing the burden of these persistent health issues.
Advancements in diagnostic techniques, such as FibroScan, Cobas TaqMan HCV Test v2.0, and RealTime HCV assay, as well as therapeutic interventions, like Pegasys, continue to evolve the management of chronic infections.
The use of statistical software, such as Stata version 14 and SAS 9.4, can help researchers analyze the data and gain insights into the epidemiology and risk factors associated with chronic infections.
Additionally, laboratory techniques, including the use of Penicillin/streptomycin, TRIzol reagent, and DNase I, play a vital role in the study and management of these persistent health conditions.
By leveraging the latest research, technologies, and analytical tools, healthcare professionals and researchers can work to enhance the understanding and treatment of chronic infections, ultimately improving the quality of life for those affected by these long-lasting health challenges.
These infections can affect different body systems and often lead to recurrent or continuous symptoms, requiring prolonged treatment for management or eradication.
Understanding the epidemiology, pathogenesis, and optimal treatment approaches for chronic infections is crucial for improving patient outcomes and reducing the burden of these persistent health issues.
Advancements in diagnostic techniques, such as FibroScan, Cobas TaqMan HCV Test v2.0, and RealTime HCV assay, as well as therapeutic interventions, like Pegasys, continue to evolve the management of chronic infections.
The use of statistical software, such as Stata version 14 and SAS 9.4, can help researchers analyze the data and gain insights into the epidemiology and risk factors associated with chronic infections.
Additionally, laboratory techniques, including the use of Penicillin/streptomycin, TRIzol reagent, and DNase I, play a vital role in the study and management of these persistent health conditions.
By leveraging the latest research, technologies, and analytical tools, healthcare professionals and researchers can work to enhance the understanding and treatment of chronic infections, ultimately improving the quality of life for those affected by these long-lasting health challenges.